#China #Ractigen #Nantong #saRNA #LICO

Ractigen Therapeutics Unveils the LiCO™ Delivery Platform

Ractigen Therapeutics, a clinical-stage biopharmaceutical company specializing in small activating RNA (saRNA) and related therapeutics, recently published a peer-reviewed study in Molecular Therapy – Nucleic Acids. This foundational research presents the innovative aspects of its proprietary LiCO™ (Lipid-Conjugated Oligonucleotide) platform, designed to enhance the delivery of oligonucleotide-based therapies beyond the liver.

Key Features of the LiCO™ Platform

The study, entitled "The LiCO Platform: A Novel Benzimidazole-Based Lipid Conjugate for Versatile and Sustained siRNA Delivery Beyond the Liver," showcases how this new delivery mechanism overcomes significant challenges in genetic medicine. The LiCO™ platform utilizes a single lipid conjugate synthesized through solid-phase chemistry, which allows for powerful and durable oligonucleotide delivery to extrahepatic organs. This is particularly important for targeting conditions affecting the skeletal muscle, heart, and adipose tissue — areas that have historically been difficult to reach with conventional RNA therapies.

Advances in Drug Delivery

Traditional RNA therapeutics have primarily focused on liver-targeted treatments. However, Ractigen’s findings suggest that their platform enables effective delivery to critical tissues that are involved in various medical conditions, including genetic neuromuscular disorders and cardiovascular diseases. The complexities involved with previous approaches, such as bulky lipid nanoparticles, are addressed with their straightforward yet effective LiCO™ architecture.

The publication outlines crucial findings, including:

• - Significant efficacy in targeting skeletal muscle, heart, and adipose tissue with over 90% mRNA knockdown demonstrated in animal models.
• - A durable therapeutic effect lasting for several months post-administration, essential for long-term disease impact.
• - The mechanism of action centers on CD36, a receptor facilitating the internalization of the oligonucleotides, reiterating the platform's focus on metabolically active tissues.

Robust Preclinical Results

Ractigen’s study showcased extensive preclinical success, particularly in cynomolgus macaques where the LiCO siMSTN showed about 90% suppression of myostatin mRNA, leading to notable muscle growth. This kind of performance underscores the platform's potential clinical applicability. The study also identified minimal systemic exposure when using localized delivery methods, suggesting a lower risk of systemic side effects compared to traditional approaches.

Progress into Clinical Trials

The innovative LiCO™ platform is not just theoretical; it has translated into two significant clinical pipelines:
1. RAG-18 — Targeting Duchenne Muscular Dystrophy (DMD), this systemic saRNA aims to enhance utrophin expression as a compensatory mechanism for dystrophin loss. Initial data presented at the 2026 World Muscle Society Congress offered encouraging insights into its potential.
2. RAG-01 — Focused on Non-Muscle Invasive Bladder Cancer (NMIBC), this local delivery treatment activates tumor suppressor genes within bladder tumors, paving the way for novel approaches in oncology.

Dr. Long-Cheng Li, founder and CEO of Ractigen Therapeutics, emphasized the importance of their publication, stating, "Our work demonstrates how the LiCO™ platform can effectively reach critical tissues that are often neglected in current therapeutic strategies.” He further noted the excitement surrounding the platform's dual validation in ongoing clinical trials, combining systemic and localized treatments that have exhibited early efficacy in patients.

Conclusion

Ractigen Therapeutics is at the forefront of revolutionizing how we approach oligonucleotide therapies. The findings from their recent study not only lay the groundwork for advanced treatments for neuromuscular and metabolic disorders but also pave the way for innovative strategies in the treatment of various cancers. With ongoing clinical trials demonstrating promising results, Ractigen showcases a future where complex diseases may be managed more effectively using cutting-edge gene therapies.

For more details, you can access the full article in Molecular Therapy – Nucleic Acids here.